| Date | Title | Description | |
|---|---|---|---|
| 02 Mar 2021 | On business and financial situation | The Company releases a presentation related to an update of the regulatory processes of its long-acting injectable antipsychotic, Doria®, both in Europe and the United States | Download |
| 24 Feb 2021 | About corporate governance | The Company informs about the agreements adopted by the Board of Directors | Download |
| 27 Nov 2020 | On business and financial situation | The Company publishes the results of the PRISMA-3 study of the efficacy and safety of Doria® in schizophrenic patients in the journal npj Schizophrenia | Download |
| 09 Jul 2020 | On business and financial situation | ROVI informs on the Collaboration with Moderna for Outside the United States Fill-Finish Manufacturing of Moderna’s COVID-19 Vaccine Candidate | Download |
Pages
| Date | Title | Description | |
|---|---|---|---|
| 27 Jul 2020 | About corporate governance | The Company informs about the agreements adopted by the Board of Directors. | Download |
| 27 Jul 2020 | On business and financial situation | ROVI releases the 2020 First Half Results presentation | Download |
| 02 Jul 2020 | Liquidity contracts and specialists | Liquidity contract: transactions conducted in the second quarter of 2020 | Download |
| 13 May 2020 | On business and financial situation | ROVI releases the presentation related to the first quarter 2020 financial results | Download |
| 13 May 2020 | Interim Management Report | The company releases the press release related to the 2020 first quarter financial results | Download |